IL-7, human recombinant
- Known as:
- Interleukin-7, H. sapiens Rec.
- Catalog number:
- BC-281
- Product Quantity:
- 10 ug
- Category:
- -
- Supplier:
- kamyia
- Gene target:
- IL-7 human recombinant
Related genes to: IL-7, human recombinant
- Gene:
- IL7 NIH gene
- Name:
- interleukin 7
- Previous symbol:
- -
- Synonyms:
- IL-7
- Chromosome:
- 8q21.13
- Locus Type:
- gene with protein product
- Date approved:
- 1989-10-12
- Date modifiied:
- 2016-10-11
- Gene:
- IL7R NIH gene
- Name:
- interleukin 7 receptor
- Previous symbol:
- -
- Synonyms:
- CD127, IL7RA
- Chromosome:
- 5p13.2
- Locus Type:
- gene with protein product
- Date approved:
- 1991-08-07
- Date modifiied:
- 2019-04-23
Related products to: IL-7, human recombinant
Related articles to: IL-7, human recombinant
- Monocytic acute myeloid leukemia (AML) is an aggressive malignancy associated with poor prognosis. High expression levels of LILRB3 and LILRB4 are commonly observed in monocytic AML. In this study, the expression of LILRB3 and LILRB4 was analyzed in monocytic AML patient samples, leukemic stem cell-enriched populations, and AML cell lines, revealing frequent co-expression and suggesting that a dual-targeting approach may provide enhanced therapeutic benefit. Accordingly, dual-targeting chimeric antigen receptor (CAR)-T cells were engineered using a single-chain variable fragment (scFv) derived from a humanized antibody capable of recognizing both LILRB3 and LILRB4. In vitro, LILRB3/4 CAR-T cells exhibited potent, antigen-dependent cytotoxicity against AML cell lines and primary blasts with minimal toxicity to normal hematopoietic stem/progenitor cells. Additionally, these CAR-T cells induced superior lysis of double-positive leukemic cells compared with single-positive populations. In both subcutaneous and systemic AML xenograft models, treatment with LILRB3/4 CAR-T cells significantly reduced tumor burden and prolonged survival. Collectively, these results demonstrate that LILRB3/4 CAR-T cells represent a promising therapeutic strategy for monocytic AML. Abbreviations: AML, Acute myeloid leukemia; BLI, Biolayer interferometry; B-NDG, NOD.CB17-Prkdc Il2rg/Bcgen; CAR-T, Chimeric antigen receptor T cell; CFSE, Carboxyfluorescein succinimidyl ester; CRS, Cytokine release syndrome; ELISA, Enzyme-linked immunosorbent assay; E:T ratio, Effector-to-target ratio; FAB, French-American-British; GM-CSF, Granulocyte-macrophage colony-stimulating factor; HSPCs, Hematopoietic stem and progenitor cells; IFN-γ, Interferon-gamma; IL-1, Interleukin-1; IL-2, Interleukin-2; IL-6, Interleukin-6; IL-7, Interleukin-7; IL-15, Interleukin-15; ITIMs, Immunoreceptor tyrosine-based inhibitory motifs; K, Equilibrium dissociation constant; LILRB, Leukocyte immunoglobulin-like receptor B; LILRB3, Leukocyte immunoglobulin-like receptor B3; LILRB4, Leukocyte immunoglobulin-like receptor B4; LSC, Leukemia stem cell; Luc, Luciferase; M4, Acute myelomonocytic leukemia; M5, Acute monocytic leukemia; MDSCs, Myeloid-derived suppressor cells; NCG, NOD/ShiLtJGpt-PrkdcIl2rg/Gpt; PBMCs, Peripheral blood mononuclear cells; PBS, Phosphate buffered saline; R/R, Relapsed/refractory; scFv, Single-chain variable fragment; SD, Standard deviation; SPF, Specific pathogen-free; SPR, Surface plasmon resonance; STAR-T, Synthetic T cell receptor and antigen receptor-T therapy; TCGA, The Cancer Genome Atlas; TNF-α, Tumor necrosis factor-alpha; TPM, Transcripts per million; VH, Variable region sequences of the heavy; VL, Variable region sequences of the light. - Source: PubMed
Publication date: 2026/07/11
Chen XiaofengGuo CuiyuTu YongyanWei XianRen QiannanYu HongbinDeng HanWu JialinChen TianZhang ZhixiongHu ZhongguoZhao ShengyanZhang GuangbingLai QinhuaiYang ShuyunZhang YingluCui SusuJiang XiaohuaZhang RuiruiWang DoudouLi DonghaoLiu HuayiGou LantuYang Jinliang - The mechanisms underlying the occurrence and development of breast cancer (BC) is complex. Vinorelbine-related genes (Vino-RGs) may play important roles in the treatment of BC, but their specific mechanisms remain unclear. We aimed to explore vinorelbine-related prognostic genes and their mechanisms for BC treatment. - Source: PubMed
Publication date: 2026/06/26
Wu YiYang GuimeiLi YixianRuan YunjingYang Qianmei - Although cannabinoids such as delta-9-tetrahydrocannabinol (THC) are generally immunosuppressive in preclinical models, chronic cannabis use in humans is paradoxically associated with increased infection risk and systemic inflammation. In this study, we demonstrate that THC directly strengthens intestinal epithelial barrier function by increasing trans-epithelial electrical resistance in a concentration-dependent manner in Caco-2 monolayers. In a cross-sectional study of chronic cannabis users via smoking or snorting compared with non-using controls, plasma lipopolysaccharide (LPS), and microbial translocation-driven inflammatory cytokines (IL-23, MCP-1, IL-8) were significantly reduced, while some cytokines (IL-6, IL-1β, TNF-α, IL-10) remained unchanged. Concurrently, users exhibited elevated macrophage-derived chemokine (MDC) and homeostatic cytokines IL-15 and IL-21, markedly suppressed IL-7 and IL-4. Plasma IL-15 and MDC levels correlated with consumption intensity, and IL-23, IL-7, and IP-10 correlated with age of first use or during heaviest use. These findings suggest that habitual cannabis use may protect gut barrier integrity and reduce microbial translocation and associated inflammation, while simultaneously disrupting systemic immune homeostasis through selective cytokine dysregulation. This dual, dose-dependent immunomodulatory profile highlights the complex balance between potential benefits and risks in both recreational and therapeutic cannabis use. - Source: PubMed
Publication date: 2026/07/03
McKinnon John EZhou ZejunWagner AmandaLuo ZhenwuHartley AliciaWan ZhuangFitting SylviaHaque AzizulMcRae-Clark AimeeJiang Wei - Human milk contains diverse immune and non-immune cellular components that change dynamically from early to established lactation. We sought to determine if the milk immune microenvironment exhibits stage-associated changes. - Source: PubMed
Publication date: 2026/06/24
Low Jia MingNg Melissa Shu FengLin Chen-ShiCui Jian-ZhouShenoy Meera KLim Sheau YngNg Lu-YiLang Si MinOng Wai-ChungFerdous TamannaGupta RashiMurali Tanusya MuraliTan IsabelleSachaphibulkij KarishmaLee Yung-SengMacAry Paul A - Interleukin-7 (IL-7) is indispensable for T cell development and homeostasis, and clinical studies have demonstrated its ability to restore T cell numbers in lymphopenic conditions. However, the therapeutic application of IL-7 has been limited by its short half-life and potential immunogenicity of recombinant variants. To overcome these challenges, we engineered a fully human tandem bispecific antibody, TB4, that functions as a potent IL-7 receptor agonist by cis-targeting IL-7 receptor alpha (IL-7Rα) and the common γ chain (γc). The tetravalent tandem scFv-Fc architecture, coupled with optimized linker length, conferred markedly enhanced binding affinity and avidity compared to the knobs-into-holes bispecific format, with domain orientation designed to limit unintended γc binding. At the cellular level, TB4 engaged both receptor subunits and exhibited reduced internalization dynamics, features that are likely to contribute to the sustained STAT5 phosphorylation observed in primary human T cells. Functionally, TB4 supported long-term T cell survival and expansion, but selectively promoted the expansion of CD4+ memory subsets, especially effector memory cells re-expressing CD45RA populations, in contrast to the broader effects of native IL-7. Transcriptomic profiling further revealed that while both TB4 and IL-7 activated proliferative gene programs, TB4 uniquely drove an antiviral and innate immune signature. Collectively, these findings establish TB4 as a next-generation IL-7R agonist antibody with a differentiated mechanism of action and potential as a precision immunomodulator that can selectively expand and reprogram T cells. - Source: PubMed
Publication date: 2026/07/08
Park Jun-KookJung InseongLee SeunghyunKim JisukShin SangheeShin JiwonNoh SoojeongKwon DahyeNam ChaerinKim HyunwookChoi HongsooYea Kyungmoo